Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
Recruiting · NCT07189455 · Interventional (participants receive a specific treatment) · Lead sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The main objective is to compare ZG006 with Investigator-Selected Chemotherapy on prolonging overall survival (OS).
Who can take part
Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Fully understand the study and voluntarily sign the informed consent form;
- Male or female 18\~75 years of age;
- Eastern Cooperative Oncology Group(ECOG) Performance Status of 0 or 1;
- Life expectancy ≥ 3 months;
- Histologically or cytologically confirmed Small Cell Lung Cancer.
Exclusion criteria
- Participants were deemed unsuitable for participating in the study by the investigator for any reason.
Where it is running
1 location listed.
- Shanghai Chest Hospital - Shanghai, Shanghai Municipality, China